Mainz Biomed (NASDAQ:MYNZ – Get Free Report) shares traded up 5.3% during mid-day trading on Thursday . The company traded as high as $0.22 and last traded at $0.21. 531,491 shares traded hands during trading, a decline of 23% from the average session volume of 691,895 shares. The stock had previously closed at $0.20.
Mainz Biomed Stock Performance
The firm’s 50-day moving average price is $0.33 and its 200-day moving average price is $0.60. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.97 and a quick ratio of 0.91. The stock has a market cap of $2.57 million, a P/E ratio of -0.13 and a beta of 0.12.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
See Also
- Five stocks we like better than Mainz Biomed
- There Are Different Types of Stock To Invest In
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Are Penny Stocks a Good Fit for Your Portfolio?
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- Using the MarketBeat Dividend Yield Calculator
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
